A 12-month study shows Neurent Medical’s radiofrequency ablation device improves symptoms and quality of life for chronic rhinitis patients.


Summary: Neurent Medical announced the publication of a 12-month study in Laryngoscope Investigative Otolaryngology demonstrating that its Neuromark system, a radiofrequency ablation device, improves symptoms and quality of life for chronic rhinitis patients. The CLARITY study highlighted improvements in nasal symptoms, safety, and quality of life.

Key Takeaways:

  • The Neuromark system reduces nasal symptoms in chronic rhinitis patients over a 12-month period.
  • The study confirmed that the Neuromark system is safe, with no serious adverse events reported.
  • Patients experienced a noticeable improvement in their quality of life after treatment with the Neuromark system.

Neurent Medical announced that a 12-month study published in Laryngoscope Investigative Otolaryngology shows its radiofrequency ablation device, the Neuromark system, improves symptoms and quality of life for chronic rhinitis patients.

Findings from the CLARITY study indicate:                

  • Symptom Reduction: All five Visual Analog Scale Nasal Symptom Score items demonstrated significant improvement (p<.0001) over baseline at all 3 time points (six, nine, and 12 months). The reflective Total Nasal Symptom Score improved from baseline at all three time points (p<.0001). A total of 91% of participants achieved the minimum clinically important difference of a reduction from baseline of ≥1 point for the reflective Total Nasal Symptom Score at 12 months.
  • Clinical Safety: The procedure showed a consistent safety profile, with no serious adverse events related to the radiofrequency ablation device observed throughout the study.
  • Quality of Life Improvement: The total mean mini Rhinoconjunctivitis Quality of Life Questionnaire significantly improved from baseline at all three time points (p<.0001). A total of 86% of participants achieved the minimum clinically important difference of a reduction from baseline of ≥0.4 points for the mini RQLQ at 12 months.
Neuromark system for chronic rhinitis. Photo credit: Neurent Medical

“This publication further validates the efficacy of our algorithm-driven patented technology for the treatment of chronic rhinitis. The publication of our device’s long-term efficacy and safety data in Laryngoscope Investigative Otolaryngology reaffirms our commitment to building strong clinical evidence to support the continued adoption of our innovative solutions that significantly improve outcomes and patient quality of life,” says Brian Shields, CEO of Neurent Medical, in a release. 

Lead investigator Douglas D. Reh, MD, adds in a release, “The CLARITY study results provide compelling evidence of sustained symptom relief and enhanced quality of life for patients suffering from chronic rhinitis. This important research better elucidates the neurovascular component of chronic rhinitis and underscores the potential of Neurent Medical’s RF ablation device as a transformative treatment option with durable relief.”

Photo 93610952 © Kowniewping | Dreamstime.com